Glucagon-Like Peptide-1 Functionalized PEG Hydrogels Promote Survival and Function of Encapsulated Pancreatic β-Cells by Lin, Chien-Chi & Anseth, Kristi S.
Glucagon-Like Peptide-1 Functionalized PEG Hydrogels
Promote Survival and Function of Encapsulated Pancreatic
-Cells
Chien-Chi Lin and Kristi S. Anseth*
Department of Chemical and Biological Engineering and the Howard Hughes Medical Institute, University
of Colorado, 424 UCB, Boulder, Colorado 80309
Received April 13, 2009; Revised Manuscript Received June 1, 2009
Encapsulating pancreatic islets in a semipermeable poly(ethylene glycol) (PEG) hydrogel membrane holds potential
as an immuno-isolation barrier for the treatment of type 1 diabetes mellitus. The semipermeable PEG hydrogel
not only permits free diffusion of nutrients, metabolic waste, and insulin produced from the encapsulated  -cells,
but also provides a size-exclusion effect to prevent direct contact of entrapped islets to host immune cells and
antibodies. However, the use of unmodiﬁed PEG hydrogels for islet encapsulation is not ideal, as there is no
bioactive cue to promote the long-term survival and function of the encapsulated cells. Herein, we report the
synthesis and characterization of a bioactive glucagon-like peptide 1 (GLP-1) analog, namely, GLP-1-cysteine or
GLP-1C, and the fabrication of functional GLP-1 immobilized PEG hydrogels via a facile thiol-acrylate
photopolymerization. The immobilization of bioactive GLP-1C within PEG hydrogels is efﬁcient and does not
alter the bulk hydrogel properties. Further, the GLP-1 immobilized PEG hydrogels enhance the survival and
insulin secretion of encapsulated islets. Overall, this study demonstrates a strategy to modify PEG hydrogels with
bioactive peptide moieties that can signiﬁcantly enhance the efﬁcacy of islet encapsulation.
Introduction
Type 1 diabetes mellitus (DM), also known as juvenile
diabetes or insulin-dependent diabetes mellitus (IDDM), is an
autoimmune disease in which the insulin-producing  -cells in
the pancreatic islets of Langerhans are destroyed by the patient’s
autoimmunity.
1 The damaged  -cells fail to produce insulin to
maintain a normal glycemia condition. Currently, administration
of insulin through daily multiple injections is a standard
treatment for type 1 DM. To alleviate patients’ reliance on daily
insulin injections, several alternatives have been proposed,
including closed-loop insulin delivery,
2 oral or nasal insulin
delivery,
3-5 and islet transplantation.
6,7 Among these alterna-
tives, islet transplantation to replace lost  -cells is considered
a better option to free the diabetic patients from insulin
dependence. Unfortunately, in conjunction with islet transplanta-
tion is life-long administration of immunosuppressants. There-
fore, this approach is only executed in diabetic patients accepting
other organ transplantations (e.g., kidney), because of the side
effects caused by the immunosuppressants.
8 Beyond problems
associated with immune rejection, the lack of long-term survival
of transplanted islets and the insufﬁcient supply of donor islets
largely hinder the clinical prevalence of islet transplantation.
9
In this regard, strategies to enhance insulin secretion from islet
 -cells (and hence decrease the number of islets needed for
transplantation) should prove valuable in the treatment of type
1 DM.
Recently, islets encapsulated in semipermeable materials such
as alginate-based microcapsules
10-12 and poly(ethylene glycol)
(PEG) hydrogels
13-19 have been suggested as an attractive
means to prevent transplanted islets from host immune destruc-
tion and to potentially decrease the needs of administrating
immunosuppressants. In particular, a semipermeable PEG
hydrogel barrier permits facile exchange of nutrients and waste
to maintain islet survival, while preventing the inﬁltration of
large immune cells and antibodies from recognizing the allo-
genic or xenogenic islet grafts. More importantly, a thin layer
of PEG hydrogel does not signiﬁcantly hinder the diffusion of
insulin secreted by encapsulated islets. Cross-linked PEG
hydrogel networks also provide a platform for facile incorpora-
tion of bioactive moieties. In vivo animal studies have revealed
the therapeutic efﬁcacy of islet-encapsulated PEG hydrogels to
treat insulin deﬁciency.
16 Although the use of PEG hydrogels
provides certain immuno-isolation to the encapsulated islets, the
encapsulated islet grafts are still challenged under the sophis-
ticated host immune response and fail to function normally in
the long term. The failure of size-exclusion barriers can be
attributed to multiple factors, such as small cytotoxic cytokines,
reactive oxygen species (ROS), and hypoxia within the gel
environments. Recent studies are therefore focused on synthe-
sizing bioactive hydrogels, rather than unmodiﬁed PEG hydro-
gels, that can actively protect encapsulated islets from the
damage originating from T-cells and ROS.
15,18 Although
intelligent, the functional moieties in these strategies do not
actively interact with the encapsulated  -cells. Therefore,
identifying bioactive cues that can actively protect  -cells as
well as developing strategies to immobilize these bioactive cues
within PEG hydrogels may enhance the long-term survival and
function of encapsulated cells.
Several therapeutic agents have been proposed to increase
the insulinotropic effect of pancreatic  -cells and to actively
protect them from apoptosis, including glucagon-like peptide 1
(GLP-1),
20-23 exendin-4 (Ex-4),
20,24 and the recently discovered
R1-antitrypsin.
25-27 The common rationale is to increase the
amount of insulin secretion and the susceptibility of islet  -cells
against apoptotic signals. Intense research efforts are currently
in progress to examine the beneﬁcial effects, as well as the
molecular mechanisms, of these therapeutic agents.
23,24 Among
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both on its glucose-dependent insulinotropic and antiapoptotic
effects to islet  -cells.
20-24 GLP-1 (7-37) is a 31-mer peptide
with a bioactive site located at the N-terminus of the pep-
tide (7His-Ala) and its inactivation is caused by the removal of
the peptide’s ﬁrst two bioactive residues by dipeptidyl peptidase
IV (DPP-IV).
22,24 Consequently, GLP-1 has an extremely short
half-live of less than 2 min in vivo.
28 To extend the circulation
half-life of GLP-1, several chemical modiﬁcation schemes have




33 and N-terminal acetylation.
34 Due to
its insulinotropic effect, GLP-1 has also been conjugated to
polymers and physically entrapped within alginate capsules for
islet encapsulation and treatment of type 1 diabetic animals.
35,36
While demonstrating an important advance, this approach
requires laborious modiﬁcation of native GLP-1 and the reaction
schemes used in these studies to immobilized GLP-1 on polymer
chains was a random conjugation between carboxylates of the
polymer chains and primary amines of GLP-1, including its
bioactive site at the N-terminus. As a result, only a limited
amount of the conjugated GLP-1 maintained bioactivity with
an unmodiﬁed N-terminus.
36 Therefore, a strategy to immobilize
GLP-1 in a polymer network without modifying the GLP-1
sequence chemically should be beneﬁcial to islet encapsulations.
Here, we aimed to fabricate bioactive GLP-1 functionalized
PEG hydrogels via thiol-acrylate photopolymerizations. Pho-
topolymerized PEG hydrogels provide a platform for facile
copolymerization of bioactive moieties to promote the survival
and functions of the encapsulated cells. Several studies have
revealed the beneﬁcial effects of incorporating extracellular
matrix (ECM) proteins in PEG hydrogels to promote the survival
of and insulin secretion from  -cells.
17,19 However, the copo-
lymerization of bioactive GLP-1 within photopolymerized PEG
hydrogels for promoting  -cells survival and functions remains
unexplored. This contribution presents an efﬁcient conjugation
scheme, namely, thiol-acrylate photopolymerizations,
37,38 to
immobilize a GLP-1 analog, GLP-1-Cysteine or GLP-1C, within
PEG-diacrylate (PEGDA) hydrogels. GLP-1C was synthesized
with an additional cysteine residue at the C-terminus of the
original GLP-1 (7-37) sequence. No additional chemical
conjugation is required following peptide synthesis and puriﬁca-
tion. Further, because the immobilization of GLP-1C in PEG
hydrogels was through a thiol-acrylate reaction, the resulting
GLP-1 immobilized PEG hydrogels should retain the full
bioactivity of GLP-1 as no conjugation/reaction occurs at the
bioactive site (N-terminus) of the peptide. Results herein show
that the bioactive GLP-1 immobilized PEG hydrogels not only
enhance the survival of pancreatic  -cells in gels but also
increases insulin secretion from islet  -cells.
Materials and Methods
Materials. Amino acids and reagents for peptide synthesis were
purchased from Anaspec (San Jose, CA). Pseudoprolinedipeptide
(Fmoc-Val-Ser(ΨMe,Mepro)-OH) was obtained from EMD Biosciences
(Gibbstown, NJ). Mouse TNFR was obtained from Abcam (Cambridge,
MA). Fluoraldehyde reagent was purchased from PIERCE (Rockford,
IL). RPMI1640, fetal bovine serum, penicillin-streptomycin, and
fungizone were obtained from Gibco (Carlsbad, CA). cAMP-Glo assay
kit, Caspase 3/7 Glo, and CellTiter-Glo cell viability kit were acquired
from Promega (Madison, WI). The mouse and rat insulin ELISA kits
were purchased from Mercodia (Winston Salem, NC). All other
chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless
noted otherwise.
Peptide Synthesis, Puriﬁcation, and Characterization. GLP-1C
(7-37C, Figure 1a) with an additional cysteine residue added to the
C-terminus of the GLP-1 (3-37) peptide sequence was synthesized
via a solid-phase peptide synthesizer (SPPS, Applied Biosystems, Model
433A). A pseudoprolinedipeptide, Fmoc-Val-Ser(ΨMe,Mepro)-OH con-
taining Val-Ser (16-17) residues, was used in the synthesis to facilitate
the synthesis of the long peptide sequence. Synthesized GLP-1C was
deprotected and cleaved from the resin for2ha troom temperature
using a cleavage cocktail, containing 5 wt % phenol in 95% TFA, 2.5%
triisopropylsilane (TIPS), and 2.5% water. The cleaved peptide was
precipitated in cold ether three times and dried at room temperature
under vacuum. Reverse phase HPLC (RP-HPLC) was used to purify
GLP-1C and the molecular weights of the collected puriﬁed fractions
were characterized with MALDI-TOF mass spectroscopy. The collected
fractions (with 95% purity) were lyophilized to obtain the pure GLP-
1C.
The laminin-derived cell adhesive peptide sequence IKVAV was
synthesized similar to the process described above. To increase the
solubility of the hydrophobic IKVAV peptide and to facilitate its
copolymerization with PEGDA, pure IKVAV was conjugated with
acryl-PEG-N-hydroxysuccinimide (acryl-PEG-NHS, Layson Bio. Inc.)
according to the literature.
39 After reaction, acryl-PEG-IKVAV was
dialyzed (MWCO: 500 Da) against dH2O for 48 h to remove unreacted
peptide. The ﬁnal product was lyophilized and stored at -20 °C until
use.
GLP-1C Bioactivity Assays.
1. cAMP Production. The bioactivity of the synthesized GLP-1C
was assayed in a rat insulinoma cell line RIN-m5F acquired from
American type Culture Collection (ATCC). The ability of GLP-1C to
elicit intracellular elevation of cAMP level was determined by cAMP-
Glo assay kit, using commercially obtained GLP-1 (Abcam Inc.,
Cambridge, MA) as positive controls. Brieﬂy, RIN-m5F cells were
seeded in a 96-well plate at a concentration of 50000 cells per well for
3 days. Before GLP-1C stimulation, cells were incubated in serum-
free RPMI for overnight. Cells were washed with HBSS (Hank’s
balanced salt solution, Invitrogen) and incubated in serum-free media
containing 500 µM IBMX (3-isobutyl-1-methylxanthine) for 15 min
to inhibit the enzymatic degradation of intracellular cAMP. Cells were
then incubated in serum-free culture media containing different
concentrations of GLP-1 or GLP-1C for 10 min. Equal volume (20
µL) of cell lysis buffer was added and incubated for another 15 min
on an orbital shaker at room temperature. The concentrations of cAMP
were quantiﬁed according to the manufacturer’s protocol.
2. Insulin Secretion. Insulin secretion from in vitro culture of RIN-
m5F cells was used to examine the bioactivity of synthesized GLP-
Figure 1. (a) Amino acid sequence of GLP-1C with its active center
(His-Ala) located at the N-terminus of the peptide and additional
cysteine residue (for thiol-acrylate photopolymerization) at the
C-terminus. (b) Mass spectrum of puriﬁed GLP-1C (7-37C) deter-
mined by MALDI-TOF mass spectroscopy. Calculated/measured
mass: 3458.80/3458.58 Da.
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plate and culture for 3 days before glucose and GLP-1C/GLP-1
stimulation. Cells were washed with HBSS and incubated in 1 mL of
Kreb-Ringer buffer solution containing 0.2 g/L glucose for 45 min,
followed by incubation in a Kreb-Ringer buffer solution containing
4.5 g/L glucose buffer for 1 h. Insulin concentrations in the high glucose
buffer solutions were measured by a rat insulin ELISA kit according
to manufacturer’s instruction.
GLP-1 Immobilized PEG Hydrogel Synthesis and Characteriza-
tion. PEGDA was synthesized by reacting 10 kDa PEG with acryloyl
chloride in toluene as described elsewhere.
40,41 PEGDA (ﬁnal concen-
tration: 10 wt %), required amount of GLP-1C, and photoinitiator I-2959
(0.025 wt % Irgacure-2959, Ciba chemical) were dissolved in PBS and
sterile-ﬁltered through a 0.2 µm ﬁlter. The macromer solutions were
exposed to UV light (365 nm, 8 mW/cm2) for 10 min to obtain GLP-1
functionalized PEG hydrogels. To quantify the GLP-1C incorporation
efﬁciency, PEG hydrogels containing predetermined concentrations of
GLP-1C (5 mm diameter × 1 mm thick) were fabricated as described
and incubated in PBS at room temperature for 48 h. After which, the
supernatants containing leached-out GLP-1C were collected and their
concentrations determined by ﬂuoraldehyde reagent according to
manufacturer’s protocol. PEG-only hydrogels encapsulated with com-
mercially available GLP-1 (obtained from Abcam) were used as a
control. Equilibrium mass swelling ratios were measured gravimetrically
and presented as a ratio of the hydrogel swollen weight to the dried
weight. The diffusion property of GLP-1 functionalized PEG hydrogels
was determined by measuring the release of bovine insulin from
hydrogels. Brieﬂy, PEG hydrogels and GLP-1 functionalized PEG
hydrogels containing 100 µMo r2 0 0µM GLP-1C were fabricated and
incubated in 1 mL bovine insulin (2 mg/mL) solution for 72 h.
Hydrogels containing bovine insulin were transferred to fresh PBS
solutions to characterize insulin release. At predetermined time intervals,
gels were transferred to an equal volume of fresh PBS and the collected
samples were stored at -80 °C until protein quantiﬁcation. Released
insulin concentrations were determined by a ﬂuorescamine assay.
42 The
release rates of insulin were not affected by the incorporation of GLP-1
within permissive PEG hydrogels (data not shown).
Encapsulation of Rat Insulinoma Cells RIN-m5F and Mouse
Islets. For encapsulation of RIN-m5F cells in PEG hydrogels, 40 µL
of trypsinized RIN-m5F cells at a ﬁnal density of 5 × 106 cells/mL
were suspended in 10 wt % PEGDA macromer solutions containing
0.025 wt % photoinitiator I-2959 and photopolymerized for 10 min.
Perpolymer solutions containing dispersed RIN-m5F  -cells were cast
inside the tip ofa1m Lsyringe with its tip cutoff. The following four
groups of hydrogels were prepared for RIN-m5F encapsulation: (1)
PEG-only hydrogels; (2) PEG hydrogels copolymerized with 2.5 mM
of laminin-derived cell adhesive peptide IKVAV; (3) PEG hydrogels
copolymerized with 10 µM GLP-1C; and (4) PEGDA hydrogels
copolymerized with 2.5 mM acryl-PEG-IKVAV and 10 µM GLP-1C.
IKVAV peptide was used to enhance the survival of encapsulated
dispersed  -cells. Encapsulated cells were maintained in RPMI1640
medium supplemented with10% FBS, 1% penicillin-streptomycin, and
0.5 µg/mL fungizone and placed on an orbital shaker (40 rpm).
Mouse islets were isolated from adult Balb/c mice in the Diabetes
and Endocrinology Research Center at the Barbara Davis Center for
Childhood Diabetes (Denver, CO). The isolated islets were digested
by type V collagenase and were puriﬁed on a Histopaque density
gradient. Isolated islets were encapsulated in PEG hydrogels with or
without GLP-1C immobilization. Brieﬂy, islets were suspended in 10
wt % PEGDA (10 kDa) solutions containing required amount of GLP-
1C (ﬁnal concentration in the prepoplymer solution: 0 or 10 µM) and
0.02 wt % photoinitiator I-2959. The islet-macromer solutions, contain-
ing approximately 20 islets per aliquot (30 µL), were injected in a
perfusion chamber mold (9 mm diameter × 0.5 mm thick, Grace Bio-
Laboratories, Bend, OR) and photopolymerized for 10 min. Note that
a IKVAV peptide is not required in the encapsulation of whole islets.
Encapsulated islets were cultured in RMPI 1640 culture media on an
orbital shaker. Culture media was changed every other day.
Encapsulated -Cell Viability and Apoptosis Assay. Viability of
the encapsulated  -cells was measured by either CellTiter-Glo reagent
or AlamarBlue reagent. CellTiter-Glo reagent quantiﬁed intracellular
ATP concentration after cell lysis, while AlamarBlue reagent measures
the metabolic activity of viable cells. For the AlmarBlue assay, 500
µL of culture media containing 10% of the AlamarBlue reagent was
added into culture media containing cell-laden gels for 4 h. The
ﬂuorescent signals (Ex: 560 nm, Em: 590 nm) of the AlamarBlue are
proportional to the number of viable cells. For CellTiter-Glo assay,
cell-laden gels were transferred to a 48-well plate containing 300 µL
of fresh culture media containing 50% of CellTiter-Glo reagent and
incubated at room temperature on an orbital shaker for 1 h. After
incubation, 200 µL of the solutions were transferred to a white-wall
96-well plate for luminescence measurements in a microplate reader.
To quantify the degree of cell apoptosis, the activity of caspase 3 was
measured using Caspase 3/7 Glo reagent with a procedure similar to
the CellTiter-Glo assay described above. The obtained caspase 3 activity
was normalized to the ﬂuorescence signal obtained from AlamarBlue
viability test in the respective gel sample. For these experiments, PEG
hydrogels without the incorporation of GLP-1C were used as controls.
Live/Dead Staining and Confocal Imaging. Cell-laden gels were
incubated in Live/Dead viability staining reagent (Invitrogen, Eugene,
OR.) containing green ﬂuorescent dye calcein AM (stains live cells)
and red ﬂuorescent dye ethidium homodimer-1 (stains dead cells) at
room temperature for1ho na norbital shaker. Stained cells were imaged
using a Zeiss LSM 5 Pascal confocal microscope. A series of z-section
images (total thickness: 500 µm) at 10 µm intervals were projected
into single plane images.
Insulin Secretion from Encapsulated Islets. The encapsulated
mouse islets were exposed to glucose solutions, and insulin secretion
was subsequently monitored. Brieﬂy, islets encapsulated in gel samples
were ﬁrst placed in a Kreb-Ringer buffer solution containing 0.2 g/L
glucose for 45 min, followed by incubation in a Kreb-Ringer buffer
solution containing 4.5 g/L glucose buffer for 1 h. Samples were
collected and stored at -80 °C until assay. The insulin concentrations
in the high glucose buffer solutions were measured by a mouse insulin
ELISA kit according to manufacturer’s instruction.
Statistical Analysis. All results are presented as mean ( SEM.
Statistical signiﬁcance was performed using a two-tailed, unpaired
Student’s t-test. Differences between groups were considered statistically
signiﬁcant when p value was less than 0.05.
Results and Discussion
GLP-1C Synthesis and Characterization. The applications
of GLP-1 to enhance insulinotropic and antiapoptotic effects
to pancreatic  -cells are well-documented.
20,23,24 However, to
effectively immobilize GLP-1 within hydrogels without com-
promising its bioactivity remains challenging with conventional
conjugation schemes that involve reactions with primary
amines.
35,36 Because the bioactive site of GLP-1 is located at
its N-terminus, random reactions on primary amines result in
the loss of the peptide bioactivity due to the conjugation to the
N-terminal primary amine. Alternatively, selective protection-de-
protection strategies can be used to achieve site-speciﬁc
conjugations, such that no reactions occur at the N-terminus of
GLP-1.
43 These strategies, however, require multiple reactions
and puriﬁcation processes. Previously, thiol-acrylate photopo-
lymerizations have been used to immobilize a variety of
bioactive peptides through the copolymerization of an additional
cysteine residue on the oligopeptides with acrylate (or ene)
functionalized PEGs.
37,38 This conjugation scheme is particular
useful in immobilizing GLP-1 within PEG hydrogels, as GLP-1
contains no cysteine residue. Thus, the conjugation/immobiliza-
tion can be designed to occur selectively between the additional
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acrylates on PEGDA macromers, leaving all the primary amines
on the GLP-1 sequence intact. To achieve this, we synthesized
a GLP-1 analog containing an extra cysteine residue at the
C-terminus of GLP-1 (7-37), or GLP-1C (Figure 1a), using
standard Fmoc chemistry in a peptide synthesizer. After peptide
synthesis and cleavage, GLP-1C was puriﬁed by RP-HPLC and
its molecular weight characterized by MALDI-TOF mass
spectroscopy. As shown in Figure 1b, we successfully synthe-
sized and puriﬁed GLP-1C with high purity (<95%, after HPLC
puriﬁcation) and accuracy (calculated/measured M.W.: 3458.80/
3458.58).
Bioactivity of GLP-1C. The bioactivity of the synthesized
GLP-1C was determined using a rat insulinoma cell line, RIN-
m5F. The mechanisms by which GLP-1-receptor binding augment
glucose-dependent insulin secretion are well-documented.
23,44
The insulinotropic effect of GLP-1 (or GLP-1C) is attributed
to the intracellular signaling events triggered by the binding of
GLP-1 to its cell surface receptors, GLP-1R. This binding causes
the elevation of intracellular cyclic AMP (cAMP) concentration.
To examine whether the synthesized GLP-1C elicits GLP-1R
binding, we quantiﬁed cAMP concentrations in an in vitro RIN-
m5F cell culture. Figure 2a shows that the intracellular cAMP
concentration increases about 2.4-fold when RIN-m5F cells were
incubated in serum-free media containing 0.1 µM of GLP-1C,
indicating that GLP-1C binds to GLP-1R and elicits intracellular
signaling. Control experiments using commercially available
GLP-1 show a similar response.
GLP-1 has also been shown to increase insulin secretion at
high glucose concentrations.
23 To examine whether the synthe-
sized GLP-1C exerts similar insulinotropic effects on pancreatic
 -cells, we incubated RIN-m5F cells in buffer solutions contain-
ing GLP-1C or GLP-1. As shown in Figure 2b, a 1.8-fold and
1.5-fold increase in insulin secretion were obtained when cells
were treated with 0.1 µM GLP-1C and GLP-1, respectively.
Taken together, the enhanced intracellular cAMP production
and increased insulin secretion demonstrate that the synthesized
GLP-1C preserves bioactivity for pancreatic  -cells, to a degree
comparable to GLP-1.
GLP-1C Immobilized PEG Hydrogel Fabrication and
Characterization. Thiol-acrylate photopolymerization is a
facile way of incorporating thiol-containing molecules, such as
cysteine-containing bioactive peptides, within PEGDA hydrogels
for enhancing the bioactivity of the otherwise inert PEG-based
hydrogels (Scheme 1). GLP-1 is an ideal candidate for this type
of incorporation because of its insulinotropic effect and that it
does not contain any native cysteine functionality in its sequence
(Figure 1a). Unlike conventional conjugation schemes that
usually involve the reactions on the primary amines of GLP-1
(including N-terminal bioactive site and two lysine residues),
the conjugation of GLP-1C in PEG hydrogels through thiol-
acrylate photopolymerization does not involve the reaction on
the primary amines. Therefore, the bioactive N-terminus of
GLP-1 should remain unmodiﬁed during polymerization and
preserve full bioactivity. Furthermore, after the peptide is
synthesized and puriﬁed, no additional conjugation is required
to render the peptide cross-linkable. A peptide release/leaching
experiment was conducted to reveal the efﬁciency of peptide
incorporation in PEG hydrogels via a thiol-acrylate photopo-
lymerization. While almost all of the GLP-1 loaded in the PEG
gels readily diffused out of the gels within 2 h, about 80% of
the incorporated GLP-1C remained in the cross-linked PEG
hydrogels (Table 1).
When introducing bioactive peptides within hydrogels through
covalent linkages, one critical consideration is that the incor-
poration of these peptides should not negatively affect the bulk
properties of the hydrogels. Swelling, for example, is particularly
important as it dictates many physical properties of PEG
hydrogels, such as mechanical properties, degradability, and
diffusivity of molecules in the cross-linked network. For islet
encapsulation, the degree of hydrogel swelling will affect the
rate of insulin diffusion, as well as nutrient-waste exchange
that is critical for maintaining islet survival in a gel environment.
It was found that the incorporation of GLP-1C within PEG
hydrogels does not alter the equilibrium mass swelling ratio
(Table 1) of PEG hydrogels and the release insulin from cell-
laden gels (data not shown), suggesting that the diffusion of
small molecules (e.g., glucose and insulin) in GLP-1C modiﬁed
PEG hydrogels was not affected. Furthermore, the geometry of
the photopolymerized PEG hydrogels can be easily manipulated
through facile molding to fulﬁll speciﬁc needs for other
applications. Because the copolymerization of thiol-containing
peptide with PEGDA is completed in a single step, this strategy
is also compatible with other islet encapsulation techniques, such
as the formation of microspheres and conformal coatings.
Enhanced -Cells Survival in GLP-1C Immobilized
Hydrogels. To assess the ability of GLP-1C immobilized PEG
hydrogels to promote pancreatic  -cells survival, we ﬁrst
encapsulated dispersed RIN-m5F cells in one of the following
four PEG gel formulations: (1) unmodiﬁed PEG hydrogels; (2)
Figure 2. Bioactivity of synthesized GLP-1C. (a) Intracellular cAMP
production in RIN-m5F cells upon treatment of GLP-1C or GLP-1
(mean ( SEM, n ) 4). Asterisks indicate statistical signiﬁcance
compared to the nontreated group (*p < 0.05). (b) In vitro insulin
secretion from RIN-m5F cells cultured in Kreb-Ringer buffer solution
containing 4.5 g/L glucose with GLP-1C or GLP-1 (mean ( SEM, n
) 4). Asterisks indicate statistical signiﬁcance compared to the
nontreated group (*p < 0.05).
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copolymerized with GLP-1C; and (4) PEG hydrogels copoly-
merized with both IKVAV and GLP-1C. It is known that the
survival of pancreatic  -cells requires either cell-cell or
cell-matrix interactions.
17,19 A laminin-derived IKVAV peptide
was used in this study, because it has been shown previously
by our group that the copolymerization of this peptide in PEG
hydrogels enhances the survival and function of dispersed
pancreatic  -cells (without cell-cell contact) in 3D hydrogel
environments.
17 To visualize cell survival in PEG-based hy-
drogels qualitatively, we ﬁrst stained the encapsulated dispersed
RIN-m5F cells with a live/dead staining kit and imaged the
encapsulated cells with confocal microscopy (Figure 3a).
Quantitatively, we also assayed the viability of RIN-m5F cells
encapsulated in PEG-based hydrogels using an AlamarBlue
reagent as well as a CellTiter-Glo reagent. AlamarBlue reagent
reduces the nonﬂuorescent indicator dye, resazurin, into red-
ﬂuorescent resoruﬁn by metabolically active cells, while Cell-
Titer-Glo reagent measures the ATP production in cells. As
shown in Figure 3a,b, the viability of dispersed RIN-m5F cells
encapsulated in unmodiﬁed PEG hydrogels decreased rapidly
over time and almost no viable cells were detected after 7 days
in gels (Figure 3a, PEG-only panel). This result veriﬁes the
importance of cell-cell and cell-matrix interactions in sup-
porting pancreatic  -cells survival in synthetic biomaterial
environment. Figure 3a also shows that while copolymerizing
IKVAV slightly enhances the viability of RIN-m5F cells, the
immobilization of a small quantity of GLP-1 (10 µM) within
PEG hydrogels greatly increases the viability of encapsulated
RIN-m5F cells, suggesting that the pro-survival effect of GLP-1
may be superior to the laminin-derived IKVAV peptide. Further,
when RIN-m5F cells were encapsulated in IKVAV/GLP-1C
copolymerized PEG gels, signiﬁcantly more viable cells,
compared to PEG-only, PEG/IKVAV, and PEG/GLP-1C gels,
are seen after a 7 day 3D culture (Figure 3a, PEG/ILVAV/GLP-
1C panel). Quantitative assessments of cell viability agree with
the qualitative observations (Figure 3b). Although the incorpora-
tion of GLP-1C in PEG hydrogels only delays, but not prevents,
the death of dispersed  -cells in PEG hydrogels, this is the ﬁrst
example of using incretin GLP-1 to promote the survival of
dispersed  -cells. Mechanistically, the binding of IKVAV to
laminin receptors on cell surface activates mitogen-activated
protein kinase/extracellular signal-regulated kinase (MAPK/
ERK) signaling pathway and promotes the survival of anchor-
age-dependent cells. Recently, studies also suggest that the
binding of GLP-1 to its trans-membrane G protein-coupled
receptor (GLP-1R) activates the MAPK/ERK pathway.
45 From
our RIN-m5F cell encapsulation results, it is possible that the
binding of immobilized GLP-1 to GLP-1R activates the signal-
ing of MAPK/ERK pathway and rescues dispersed  -cells from
apoptosis induced by the deprivation of cell-cell/cell-matrix
interactions. However, further investigations on the intracellular
signaling pathway are needed to reveal the molecular mecha-
nisms related to GLP-1R signaling and cell survival in 3D
hydrogels.
Mouse Islet Encapsulation in GLP-1C Functionalized
PEG Hydrogels. In previous publications, PEG hydrogels
formed via photopolymerization techniques have been success-
fully used to encapsulate mouse islets for in vitro as well as in
vivo studies.
16,17,19 Although the fabrication of PEG hydrogels
via photopolymerizations produces a stable network rapidly and
has been applied to encapsulate a variety of cell types, the
generation of free radicals during the chain polymerization
reaction may cause a certain degree of cell damage. To reveal
the photopolymerization-induced damage on encapsulated islets,
we stained and imaged encapsulated mouse islets right after
photopolymerization. As shown in Figure 4a, dead cells
(evidenced by the binding of red ﬂuorescent dye, ethidium
homodimer-1, to the exposed DNA of dead cells) are clearly
Scheme 1. Mechanism of Thiol-Acrylate Photopolymerization with -SH Groups from GLP-1C and Acrylate Groups from PEGDA
a
a Reaction is shown only on one side of the PEGDA.
Table 1. Characterization of Hydrogel Swelling and GLP-1C Incorporation
peptide leaching (%)
[GLP-1C] (µM) Qm
a 1h 2h 4h 2 4h
b
0 15.4 ( 0.59
100 15.1 ( 0.56 12.8 ( 0.64 16.2 ( 1.43 16.9 ( 1.17 18.4 ( 0.29
200 14.8 ( 0.75 16.5 ( 1.53 23.2 ( 4.39 20.7 ( 1.32 22.4 ( 1.13
100 µM GLP-1 16.0 ( 1.45 79.3 ( 6.09 97.2 ( 4.49 101 ( 0.17 n.d.
a Qm ) swollen gel wt/dried polymer wt.
b No further GLP-1C leaching was detected after 24 h.
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surface of the islet. Because the staining was done immediately
after photopolymerization, it is reasonable to suggest that the
cell damage was caused by the polymerization process and could
be a result of radical-mediated cell death or apoptosis. Interest-
ingly, when isolated islets were photoencapsulated in PEG
hydrogels in the presence of GLP-1C, the amount of dead cells
decreased dramatically (Figure 4b). This result suggests a
potential cyto-protective effect of GLP-1 to islet cells during
radical-mediated photoencapsulation. One previous study re-
vealed an antiapoptotic effect of GLP-1, via PI3-kinase (PI3K)
pathway, to pancreatic  -cells under the challenge of H2O2.
46
We reason that GLP-1 (or GLP-1C) may exhibit a similar
protective mechanism for islet cells during radical-mediated
photopolymerization. Further studies, however, are required to
validate this hypothesis.
To assess the protective effects of immobilized GLP-1 on
encapsulated islets, we incorporated GLP-1C at different
concentrations in PEG hydrogels via thiol-acrylate photopo-
lymerizations. Figure 4c shows that in GLP-1C functionalized
PEG hydrogels, the level of intracellular ATP was signiﬁcantly
higher at high GLP-1C concentrations, compared to unmodiﬁed
PEG hydrogels (7 days after photoencapsulation). This dem-
onstrates that the immobilization of GLP-1C within PEG
hydrogels enhances the survival of isolated islets. Further, Figure
4d shows the results of glucose-stimulated insulin secretion from
encapsulated islets 7 days after photoencapsulation. It can be
seen that the incorporation of GLP-1C in PEG hydrogels greatly
enhances insulin secretion by about 2.5-fold, when compared
to unmodiﬁed PEG hydrogels. We also discovered that the
immobilization of GLP-1C in PEG hydrogels does not signiﬁ-
cantly change the level of insulin secretion at low glucose (0.2
Figure 3. (a) Representative confocal z-section stacking images of encapsulated RIN-m5F cells at 3 days and 7 days. Cells were stained with
Live/Dead cell viability kit (scale bar ) 100 µm). (b) Quantiﬁcation of encapsulated RIN-m5F cell survival in PEG hydrogels with indicated
compositions determined by CellTiter-Glo assay (mean ( SEM, n ) 4). Asterisks indicate statistical signiﬁcance between experimental groups
and the unmodiﬁed PEG gels [(-) IKVAV, (-) GLP-1C] at the respective time point (p < 0.05). (c) Antiapoptotic effect of immobilized GLP-1C
on encapsulated RIN-m5F cells 3 days after encapsulation. Luminescence signals of the caspase 3/7 activity were normalized by the AlamarBlue
ﬂuorescence of the respective gel sample to account for the variance of viable cells (mean ( SEM, n ) 3; *p < 0.05).
Function of Encapsulated Pancreatic  -Cells Biomacromolecules, Vol. 10, No. 9, 2009 2465g/L) concentration (data not shown). This phenomenon coincides
with previous studies that the insulinotropic effect of GLP-1 is
dependent on glucose concentrations.
22
Antiapoptotic Effect of Immobilized GLP-1 to Encap-
sulated -Cells. Previous studies have shown that the survival
of pancreatic  -cells encapsulated in PEG hydrogels relies
heavily on cell-cell and cell-matrix interactions.
16,17,19 As a
result,  -cells undergo apoptosis rapidly when encapsulated as
single cells in PEG hydrogels. Although GLP-1 is not an
extracellular matrix protein, it does provide antiapoptotic effects
to stimuli-challenged  -cells via activation of PI3-kinase (PI3K)
and MAPK/ERK pathways.
45-47 The immobilization of GLP-1
within PEG hydrogels may therefore provide antiapoptotic to
the encapsulated cells. As shown in Figure 3c, when encapsu-
lated as dispersed cells, RIN-m5F cells undergo a higher level
of apoptosis in PEG-only hydrogels than in IKVAV or GLP-
1C functionalized PEG hydrogels. Interestingly, the antiapoptotic
effect was more signiﬁcant when both IKVAV and GLP-1 were
copolymerized within PEG hydrogels, suggesting a potential
synergistic effect of the ECM peptide IKVAV and incretin
hormone GLP-1 on the intracellular antiapoptotic signaling.
Figure 5 shows a similar antiapoptotic effect of immobilized
GLP-1 on encapsulated mouse islets.
The signaling of GLP-1 to pancreatic  -cells has been a
subject of intensive research. In addition to its glucose-dependent
insulinotropic effect, GLP-1 or its receptor agonists (e.g.,
Exendin 4) also exhibits pro-survival or antiapoptotic effects
Figure 4. (a) Representative confocal z-section stacking image of
a mouse islet encapsulated in PEGDA-only hydrogel. (b) Repre-
sentative confocal z-section stacking image of a mouse islet
encapsulated in GLP-1 immobilized PEGDA hydrogel. (Encapsu-
lated islets were stained with live/dead staining kit and imaged
right after photopolymerization.) (c) Encapsulated mouse islet
survival after 7 days (CellTiter-Glo ATP production assay) in PEG
hydrogels incorporated with various GLP-1C concentrations (mean
( SEM, n ) 4). (d) Insulin secretion from mouse islets encapsu-
lated in PEG hydrogels (7 days) incorporated with various GLP-
1C concentrations (mean ( SEM, n ) 4). Asterisks indicate
statistical signiﬁcance compared to unmodiﬁed PEG gels (*p <
0.05).
Figure 5. Antiapoptotic effect of immobilized GLP-1 on isolated mouse
islets encapsulated in PEG gels (3 days after encapsulation, mean
( SEM, n ) 3). The relative luminescence units (RLU) of the caspase
3/7 activity were normalized by the number of islets encapsulated in
the respective gel (*p < 0.05).
Figure 6. Relative islet cell survival in PEG hydrogels or PEG-GLP-1
hydrogels (10 µM GLP-1C) under 50 ng/mL TNFR challenge for 48 h
(3 days after encapsulation) as determined by CellTiter-Glo assay
for ATP production (mean ( SEM, n ) 3; *p < 0.05 compared to
islets in PEG hydrogels without TNFR challenge).
2466 Biomacromolecules, Vol. 10, No. 9, 2009 Lin and Ansethon pancreatic  -cells under a variety of biological/chemical
stimuli, including pro-inﬂammatory cytokines (e.g., TNFR, IL-
 ).
45 Recent studies have revealed that the beneﬁcial effects of
GLP-1 on  -cells in the presence of pro-apoptotic signals are
the results of GLP-1R activated signaling pathways, including
cAMP/protein kinase A (PKA), PI3K, and MAPK/ERK
pathways.
23,45-47 To elucidate the antiapoptotic effect of im-
mobilized GLP-1 against cytokine challenge, we incubated
encapsulated islets in media supplemented with TNFR (50
ng/mL).
48-50 Because TNFR is a small molecule with a
molecular weight of approximately 17.4 kDa, it inﬁltrates the
highly permeable PEG hydrogels rapidly (data not shown). Upon
binding to TNF-R, TNFR triggers an apoptotic pathway that
leads to islet cell death. As shown in Figure 6, the survival of
islets encapsulated in GLP-1 immobilized PEG hydrogels was
higher than in unmodiﬁed PEG hydrogels under TNFR challenge.
Conclusions
In conclusion, we have successfully synthesized a GLP-1
analog, GLP-1C, and fabricated bioactive GLP-1 functionalized
hydrogels via a thiol-acrylate photopolymerization for pan-
creatic  -cell encapsulation. The physical properties, such as
gel swelling and molecular transport, of PEG hydrogels were
not affected by the copolymerization with GLP-1C. Compared
to PEG hydrogels, pancreatic  -cells (RIN-m5F) and mouse
islets encapsulated in GLP-1C immobilized PEG hydrogels had
higher viability and secreted more insulin upon glucose stimula-
tion. Further,  -cells encapsulated in bioactive GLP-1C im-
mobilized PEG hydrogels were less apoptotic than those
encapsulated in unmodiﬁed PEG hydrogels. The current work
augments the therapeutic efﬁcacy of PEG hydrogels in encap-
sulating pancreatic islets to treat type 1 DM and should prove
useful in future in vivo studies.
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